产品说明书

Ornidazole

Print
Chemical Structure| 16773-42-5 同义名 : Ro 7-0207;NSC 95075;Tiberal;(±)-Ornidazole
CAS号 : 16773-42-5
货号 : A213162
分子式 : C7H10ClN3O3
纯度 : 98%
分子量 : 219.626
MDL号 : MFCD00057960
存储条件:

粉末 Sealed in dry,Room Temperature

液体 -20°C:3-6个月-80°C:12个月

溶解度 :

DMSO: 105 mg/mL(478.09 mM),注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO

H2O: 10 mg/mL(45.53 mM),配合低频超声助溶

动物实验配方:
生物活性
描述 Ornidazole is a 5-nitroimidazole derivative with antiprotozoal and antibacterial properties against anaerobic bacteria. Ornidazole 1 g/day is effective for the prevention of recurrence of Crohn's disease after ileocolonic resection[3]. Adverse effects on the central nervous system (CNS) are the main side effects of ornidazole during its clinical application[4]. A concentration of 3. 1 mg/mL of ornidazole inhibited 98% of the strains of B. fragilis, with greater sensitivity when ampicillin and gentamicin were also present. A concentration of 6. 2 mg/mL of ornidazole inhibited 16 of 18 strains of C. perfringens and all 11 strains of other Clostridium species[5]. Moreover, ornidazole loaded fibers could be a potential drug delivery system for the treatment of gingivitis[6].
临床研究
NCT号 适应症或疾病 临床期 招募状态 预计完成时间 地点
NCT01662765 - Completed - -
NCT00609973 Crohn's Disease Phase 2 Completed - United States, North Carolina ... 展开 >> University of North Carolina Chapel Hill, North Carolina, United States, 27599 收起 <<
NCT01662765 Pilonidal Sinus ... 展开 >> Sinus; Dermal, Pilonidal Umbilical Granuloma 收起 << Not Applicable Completed - Turkey ... 展开 >> Hatem Hospital Gaziantep, Turkey, 27090 Medical Park Gaziantep Hospital Gaziantep, Turkey, 27090 25 Aralık Familiy Physician Health Center Gaziantep, Turkey, 27100 Dr.Ersin Arslan State Hospital Gaziantep, Turkey, 27100 Şehitkamil State Hospital Gaziantep, Turkey, 27100 收起 <<
实验方案
1mg 5mg 10mg

1 mM

5 mM

10 mM

4.55mL

0.91mL

0.46mL

22.77mL

4.55mL

2.28mL

45.53mL

9.11mL

4.55mL

参考文献

[1]Rutgeerts P, Van Assche G, et al. Ornidazole for prophylaxis of postoperative Crohn's disease recurrence: a randomized, double-blind, placebo-controlled trial. Gastroenterology. 2005 Apr;128(4):856-61.

[2]Goldstein EJ, Sutter VL, Finegold SM. Comparative susceptibilities of anaerobic bacteria to metronidazole, ornidazole, and SC-28538. Antimicrob Agents Chemother. 1978 Oct;14(4):609-13.

[3]Rutgeerts P, Van Assche G, Vermeire S, D'Haens G, Baert F, Noman M, Aerden I, De Hertogh G, Geboes K, Hiele M, D'Hoore A, Penninckx F. Ornidazole for prophylaxis of postoperative Crohn's disease recurrence: a randomized, double-blind, placebo-controlled trial. Gastroenterology. 2005 Apr;128(4):856-61. doi: 10.1053/j.gastro.2005.01.010. PMID: 15825069.

[4]Wei TT, Sun JH, Han LW, Chen K, Wang ZQ, Ji H. Effects of the ornidazole enantiomers on the central nervous system: Involvement of the GABAA receptor. Chem Biol Interact. 2015 Dec 5;242:163-9. doi: 10.1016/j.cbi.2015.09.019. Epub 2015 Sep 26. PMID: 26415617.

[5]Palmu A, Renkonen OV, Aromaa U. Ornidazole and anaerobic bacteria: in vitro sensitivity and effects on wound infections after appendectomy. J Infect Dis. 1979 May;139(5):586-9. doi: 10.1093/infdis/139.5.586. PMID: 220342.

[6]Tort S, Yıldız A, Tuğcu-Demiröz F, Akca G, Kuzukıran Ö, Acartürk F. Development and characterization of rapid dissolving ornidazole loaded PVP electrospun fibers. Pharm Dev Technol. 2019 Sep;24(7):864-873. doi: 10.1080/10837450.2019.1615088. Epub 2019 Jun 7. PMID: 31046546.